Clinical characterization and outcome of primary bone lymphoma: a retrospective study of 61 Chinese patients
Primary bone lymphoma(PBL) is a rare disease. To assess the clinical characteristics, outcome, and prognostic factors of this entity in Chinese population, we retrospectively analyzed 61 PBL patients initially treated in our institution between 1997 and 2014. The median age was 45 years. The most co...
Gespeichert in:
| Veröffentlicht in: | Scientific reports 2016-06, Vol.6 (1), p.28834-28834, Article 28834 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 28834 |
|---|---|
| container_issue | 1 |
| container_start_page | 28834 |
| container_title | Scientific reports |
| container_volume | 6 |
| creator | Zhang, XuanYe Zhu, Jun Song, YuQin Ping, LingYan Zheng, Wen |
| description | Primary bone lymphoma(PBL) is a rare disease. To assess the clinical characteristics, outcome, and prognostic factors of this entity in Chinese population, we retrospectively analyzed 61 PBL patients initially treated in our institution between 1997 and 2014. The median age was 45 years. The most common histological subtype was diffuse large B-cell lymphoma (DLBCL) (55.7%), followed by T-cell lymphoma (18.0%). All patients underwent systemic chemotherapy as initial treatment while 24 patients (39.3%) were additionally treated with radiotherapy. The 5-year overall survival (OS) and the 5-year progression-free survival (PFS) rates of 57 cases with completed follow-up were 52.3% and 40.1%, respectively. In further analysis of the primary bone DLBCL (PB-DLBCL) subgroup, the 5-year OS and PFS rates were 53.0% and 47.0%, and a multivariable analysis revealed that baseline Eastern Cooperative Oncology Group (ECOG) score and response to initial treatment (complete remission versus no complete remission) were independent prognostic factors for both OS and PFS. The proportion of T-cell lymphoma is higher in China than in western populations. High baseline ECOG scores (≥2) and unachieved CR in initial therapy were factors for poor PB-DLBCL prognosis. The role of radiotherapy and rituximab in PLB therapy remains to be confirmed in further investigation. |
| doi_str_mv | 10.1038/srep28834 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4928085</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1801437321</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-cd6a9120748dae41046076a3c1265e60194788826d8faa25e5cc5d8584df3e1b3</originalsourceid><addsrcrecordid>eNplkU2LFDEQhoMo7rLuwT8gAS8qjOazO-1hQQa_YMGLnkNNunonS3fSJumF8debYcZh1CJQBfXwVlVeQp5z9pYzad7lhLMwRqpH5FIwpVdCCvH4rL4g1znfsxpadIp3T8mFaKWuT12ScT364B2M1G0hgSuY_C8oPgYKoadxKS5OSONA5-QnSDu6iQHpuJvmbZzgPQWasKSYZ3TFPyDNZel3e77hdL31ATPSuQpiKPkZeTLAmPH6mK_Ij08fv6-_rG6_ff66_nC7ckqasnJ9Ax0XrFWmB1ScqYa1DUjHRaOxYbxTrTFGNL0ZAIRG7ZzujTaqHyTyjbwiNwfdedlM2Ls6O8FojxfYCN7-3Ql-a-_ig1WdMMzoKvDqKJDizwVzsZPPDscRAsYlW24YV7KVglf05T_ofVxSqOftKSNlUy2o1OsD5epXVceG0zKc2b2N9mRjZV-cb38i_5hWgTcHINdWuMN0NvI_td9nTKet</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1808336322</pqid></control><display><type>article</type><title>Clinical characterization and outcome of primary bone lymphoma: a retrospective study of 61 Chinese patients</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Springer Nature OA Free Journals</source><source>Nature Free</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>Zhang, XuanYe ; Zhu, Jun ; Song, YuQin ; Ping, LingYan ; Zheng, Wen</creator><creatorcontrib>Zhang, XuanYe ; Zhu, Jun ; Song, YuQin ; Ping, LingYan ; Zheng, Wen</creatorcontrib><description>Primary bone lymphoma(PBL) is a rare disease. To assess the clinical characteristics, outcome, and prognostic factors of this entity in Chinese population, we retrospectively analyzed 61 PBL patients initially treated in our institution between 1997 and 2014. The median age was 45 years. The most common histological subtype was diffuse large B-cell lymphoma (DLBCL) (55.7%), followed by T-cell lymphoma (18.0%). All patients underwent systemic chemotherapy as initial treatment while 24 patients (39.3%) were additionally treated with radiotherapy. The 5-year overall survival (OS) and the 5-year progression-free survival (PFS) rates of 57 cases with completed follow-up were 52.3% and 40.1%, respectively. In further analysis of the primary bone DLBCL (PB-DLBCL) subgroup, the 5-year OS and PFS rates were 53.0% and 47.0%, and a multivariable analysis revealed that baseline Eastern Cooperative Oncology Group (ECOG) score and response to initial treatment (complete remission versus no complete remission) were independent prognostic factors for both OS and PFS. The proportion of T-cell lymphoma is higher in China than in western populations. High baseline ECOG scores (≥2) and unachieved CR in initial therapy were factors for poor PB-DLBCL prognosis. The role of radiotherapy and rituximab in PLB therapy remains to be confirmed in further investigation.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/srep28834</identifier><identifier>PMID: 27357354</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>13 ; 13/56 ; 692/308/409 ; 692/699/2743/316 ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Asian Continental Ancestry Group ; Bone marrow ; Bone Neoplasms - drug therapy ; Bone Neoplasms - mortality ; Bone Neoplasms - pathology ; Bone Neoplasms - radiotherapy ; Chemotherapy ; China ; Combined Modality Therapy ; Disease-Free Survival ; Female ; Humanities and Social Sciences ; Humans ; Kaplan-Meier Estimate ; Lymphatic system ; Lymphoma ; Lymphoma, Large B-Cell, Diffuse - drug therapy ; Lymphoma, Large B-Cell, Diffuse - mortality ; Lymphoma, Large B-Cell, Diffuse - pathology ; Lymphoma, Large B-Cell, Diffuse - radiotherapy ; Lymphoma, T-Cell - drug therapy ; Lymphoma, T-Cell - mortality ; Lymphoma, T-Cell - pathology ; Lymphoma, T-Cell - radiotherapy ; Male ; Medical prognosis ; Middle Aged ; multidisciplinary ; Multivariate Analysis ; Neoplasm Staging ; Positron Emission Tomography Computed Tomography ; Prognosis ; Radiation therapy ; Rare diseases ; Remission (Medicine) ; Remission Induction ; Retrospective Studies ; Rituximab - therapeutic use ; Science ; Survival analysis ; Tomography ; Tomography, X-Ray Computed ; Treatment Outcome ; Ultrasonic imaging ; Young Adult</subject><ispartof>Scientific reports, 2016-06, Vol.6 (1), p.28834-28834, Article 28834</ispartof><rights>The Author(s) 2016</rights><rights>Copyright Nature Publishing Group Jun 2016</rights><rights>Copyright © 2016, Macmillan Publishers Limited 2016 Macmillan Publishers Limited</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-cd6a9120748dae41046076a3c1265e60194788826d8faa25e5cc5d8584df3e1b3</citedby><cites>FETCH-LOGICAL-c438t-cd6a9120748dae41046076a3c1265e60194788826d8faa25e5cc5d8584df3e1b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928085/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928085/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27923,27924,41119,42188,51575,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27357354$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, XuanYe</creatorcontrib><creatorcontrib>Zhu, Jun</creatorcontrib><creatorcontrib>Song, YuQin</creatorcontrib><creatorcontrib>Ping, LingYan</creatorcontrib><creatorcontrib>Zheng, Wen</creatorcontrib><title>Clinical characterization and outcome of primary bone lymphoma: a retrospective study of 61 Chinese patients</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>Primary bone lymphoma(PBL) is a rare disease. To assess the clinical characteristics, outcome, and prognostic factors of this entity in Chinese population, we retrospectively analyzed 61 PBL patients initially treated in our institution between 1997 and 2014. The median age was 45 years. The most common histological subtype was diffuse large B-cell lymphoma (DLBCL) (55.7%), followed by T-cell lymphoma (18.0%). All patients underwent systemic chemotherapy as initial treatment while 24 patients (39.3%) were additionally treated with radiotherapy. The 5-year overall survival (OS) and the 5-year progression-free survival (PFS) rates of 57 cases with completed follow-up were 52.3% and 40.1%, respectively. In further analysis of the primary bone DLBCL (PB-DLBCL) subgroup, the 5-year OS and PFS rates were 53.0% and 47.0%, and a multivariable analysis revealed that baseline Eastern Cooperative Oncology Group (ECOG) score and response to initial treatment (complete remission versus no complete remission) were independent prognostic factors for both OS and PFS. The proportion of T-cell lymphoma is higher in China than in western populations. High baseline ECOG scores (≥2) and unachieved CR in initial therapy were factors for poor PB-DLBCL prognosis. The role of radiotherapy and rituximab in PLB therapy remains to be confirmed in further investigation.</description><subject>13</subject><subject>13/56</subject><subject>692/308/409</subject><subject>692/699/2743/316</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Asian Continental Ancestry Group</subject><subject>Bone marrow</subject><subject>Bone Neoplasms - drug therapy</subject><subject>Bone Neoplasms - mortality</subject><subject>Bone Neoplasms - pathology</subject><subject>Bone Neoplasms - radiotherapy</subject><subject>Chemotherapy</subject><subject>China</subject><subject>Combined Modality Therapy</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Lymphatic system</subject><subject>Lymphoma</subject><subject>Lymphoma, Large B-Cell, Diffuse - drug therapy</subject><subject>Lymphoma, Large B-Cell, Diffuse - mortality</subject><subject>Lymphoma, Large B-Cell, Diffuse - pathology</subject><subject>Lymphoma, Large B-Cell, Diffuse - radiotherapy</subject><subject>Lymphoma, T-Cell - drug therapy</subject><subject>Lymphoma, T-Cell - mortality</subject><subject>Lymphoma, T-Cell - pathology</subject><subject>Lymphoma, T-Cell - radiotherapy</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>multidisciplinary</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Staging</subject><subject>Positron Emission Tomography Computed Tomography</subject><subject>Prognosis</subject><subject>Radiation therapy</subject><subject>Rare diseases</subject><subject>Remission (Medicine)</subject><subject>Remission Induction</subject><subject>Retrospective Studies</subject><subject>Rituximab - therapeutic use</subject><subject>Science</subject><subject>Survival analysis</subject><subject>Tomography</subject><subject>Tomography, X-Ray Computed</subject><subject>Treatment Outcome</subject><subject>Ultrasonic imaging</subject><subject>Young Adult</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNplkU2LFDEQhoMo7rLuwT8gAS8qjOazO-1hQQa_YMGLnkNNunonS3fSJumF8debYcZh1CJQBfXwVlVeQp5z9pYzad7lhLMwRqpH5FIwpVdCCvH4rL4g1znfsxpadIp3T8mFaKWuT12ScT364B2M1G0hgSuY_C8oPgYKoadxKS5OSONA5-QnSDu6iQHpuJvmbZzgPQWasKSYZ3TFPyDNZel3e77hdL31ATPSuQpiKPkZeTLAmPH6mK_Ij08fv6-_rG6_ff66_nC7ckqasnJ9Ax0XrFWmB1ScqYa1DUjHRaOxYbxTrTFGNL0ZAIRG7ZzujTaqHyTyjbwiNwfdedlM2Ls6O8FojxfYCN7-3Ql-a-_ig1WdMMzoKvDqKJDizwVzsZPPDscRAsYlW24YV7KVglf05T_ofVxSqOftKSNlUy2o1OsD5epXVceG0zKc2b2N9mRjZV-cb38i_5hWgTcHINdWuMN0NvI_td9nTKet</recordid><startdate>20160630</startdate><enddate>20160630</enddate><creator>Zhang, XuanYe</creator><creator>Zhu, Jun</creator><creator>Song, YuQin</creator><creator>Ping, LingYan</creator><creator>Zheng, Wen</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160630</creationdate><title>Clinical characterization and outcome of primary bone lymphoma: a retrospective study of 61 Chinese patients</title><author>Zhang, XuanYe ; Zhu, Jun ; Song, YuQin ; Ping, LingYan ; Zheng, Wen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-cd6a9120748dae41046076a3c1265e60194788826d8faa25e5cc5d8584df3e1b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>13</topic><topic>13/56</topic><topic>692/308/409</topic><topic>692/699/2743/316</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Asian Continental Ancestry Group</topic><topic>Bone marrow</topic><topic>Bone Neoplasms - drug therapy</topic><topic>Bone Neoplasms - mortality</topic><topic>Bone Neoplasms - pathology</topic><topic>Bone Neoplasms - radiotherapy</topic><topic>Chemotherapy</topic><topic>China</topic><topic>Combined Modality Therapy</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Lymphatic system</topic><topic>Lymphoma</topic><topic>Lymphoma, Large B-Cell, Diffuse - drug therapy</topic><topic>Lymphoma, Large B-Cell, Diffuse - mortality</topic><topic>Lymphoma, Large B-Cell, Diffuse - pathology</topic><topic>Lymphoma, Large B-Cell, Diffuse - radiotherapy</topic><topic>Lymphoma, T-Cell - drug therapy</topic><topic>Lymphoma, T-Cell - mortality</topic><topic>Lymphoma, T-Cell - pathology</topic><topic>Lymphoma, T-Cell - radiotherapy</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>multidisciplinary</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Staging</topic><topic>Positron Emission Tomography Computed Tomography</topic><topic>Prognosis</topic><topic>Radiation therapy</topic><topic>Rare diseases</topic><topic>Remission (Medicine)</topic><topic>Remission Induction</topic><topic>Retrospective Studies</topic><topic>Rituximab - therapeutic use</topic><topic>Science</topic><topic>Survival analysis</topic><topic>Tomography</topic><topic>Tomography, X-Ray Computed</topic><topic>Treatment Outcome</topic><topic>Ultrasonic imaging</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, XuanYe</creatorcontrib><creatorcontrib>Zhu, Jun</creatorcontrib><creatorcontrib>Song, YuQin</creatorcontrib><creatorcontrib>Ping, LingYan</creatorcontrib><creatorcontrib>Zheng, Wen</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, XuanYe</au><au>Zhu, Jun</au><au>Song, YuQin</au><au>Ping, LingYan</au><au>Zheng, Wen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical characterization and outcome of primary bone lymphoma: a retrospective study of 61 Chinese patients</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2016-06-30</date><risdate>2016</risdate><volume>6</volume><issue>1</issue><spage>28834</spage><epage>28834</epage><pages>28834-28834</pages><artnum>28834</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>Primary bone lymphoma(PBL) is a rare disease. To assess the clinical characteristics, outcome, and prognostic factors of this entity in Chinese population, we retrospectively analyzed 61 PBL patients initially treated in our institution between 1997 and 2014. The median age was 45 years. The most common histological subtype was diffuse large B-cell lymphoma (DLBCL) (55.7%), followed by T-cell lymphoma (18.0%). All patients underwent systemic chemotherapy as initial treatment while 24 patients (39.3%) were additionally treated with radiotherapy. The 5-year overall survival (OS) and the 5-year progression-free survival (PFS) rates of 57 cases with completed follow-up were 52.3% and 40.1%, respectively. In further analysis of the primary bone DLBCL (PB-DLBCL) subgroup, the 5-year OS and PFS rates were 53.0% and 47.0%, and a multivariable analysis revealed that baseline Eastern Cooperative Oncology Group (ECOG) score and response to initial treatment (complete remission versus no complete remission) were independent prognostic factors for both OS and PFS. The proportion of T-cell lymphoma is higher in China than in western populations. High baseline ECOG scores (≥2) and unachieved CR in initial therapy were factors for poor PB-DLBCL prognosis. The role of radiotherapy and rituximab in PLB therapy remains to be confirmed in further investigation.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>27357354</pmid><doi>10.1038/srep28834</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-2322 |
| ispartof | Scientific reports, 2016-06, Vol.6 (1), p.28834-28834, Article 28834 |
| issn | 2045-2322 2045-2322 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4928085 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Springer Nature OA Free Journals; Nature Free; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry |
| subjects | 13 13/56 692/308/409 692/699/2743/316 Adolescent Adult Aged Aged, 80 and over Asian Continental Ancestry Group Bone marrow Bone Neoplasms - drug therapy Bone Neoplasms - mortality Bone Neoplasms - pathology Bone Neoplasms - radiotherapy Chemotherapy China Combined Modality Therapy Disease-Free Survival Female Humanities and Social Sciences Humans Kaplan-Meier Estimate Lymphatic system Lymphoma Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - mortality Lymphoma, Large B-Cell, Diffuse - pathology Lymphoma, Large B-Cell, Diffuse - radiotherapy Lymphoma, T-Cell - drug therapy Lymphoma, T-Cell - mortality Lymphoma, T-Cell - pathology Lymphoma, T-Cell - radiotherapy Male Medical prognosis Middle Aged multidisciplinary Multivariate Analysis Neoplasm Staging Positron Emission Tomography Computed Tomography Prognosis Radiation therapy Rare diseases Remission (Medicine) Remission Induction Retrospective Studies Rituximab - therapeutic use Science Survival analysis Tomography Tomography, X-Ray Computed Treatment Outcome Ultrasonic imaging Young Adult |
| title | Clinical characterization and outcome of primary bone lymphoma: a retrospective study of 61 Chinese patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T02%3A32%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20characterization%20and%20outcome%20of%20primary%20bone%20lymphoma:%20a%20retrospective%20study%20of%2061%20Chinese%20patients&rft.jtitle=Scientific%20reports&rft.au=Zhang,%20XuanYe&rft.date=2016-06-30&rft.volume=6&rft.issue=1&rft.spage=28834&rft.epage=28834&rft.pages=28834-28834&rft.artnum=28834&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/srep28834&rft_dat=%3Cproquest_pubme%3E1801437321%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1808336322&rft_id=info:pmid/27357354&rfr_iscdi=true |